ImmuPharma doses patients in Lupus phase 2 trial

By Elaine Rigoli

Tampa, Fla., July 5 - ImmuPharma plc said its IPP-201101 treatment for lupus, a chronic, life-threatening autoimmune disease, has entered into phase 2 clinical trials and the first group of patients have already been given the drug.

This European phase 2 study is a proof-of-concept, dose-ranging, safety and efficacy study. The efficacy will be assessed using appropriate surrogate markers that are involved in the disease and biomarkers related to mechanism of action of IPP-201101, according to a news release.

Results from this short duration study, expected by year-end, will enable the preparation of pivotal phase 3 studies.

This follows the successful completion in May of a placebo-controlled phase 1 study involving 24 healthy volunteers to assess its safety and tolerability. The preliminary safety report confirmed that the drug was safe and well-tolerated.

ImmuPharma is a drug-discovery and development company with headquarters in London.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.